Spotlight Reports 2018-04-04T16:33:58+00:00

Report Spotlights

RealTime Dynamix™: Psoriasis US Q2 2018 Spotlight

Spherix’s Q2 update of RealTime Dynamix™: Psoriasis (US) reveals significant changes afoot in the current psoriasis biologic landscape. Year-over-year analysis indicates continued erosion of the established agents, such as AbbVie’s Humira, Amgen’s Enbrel, and Janssen’s Stelara, in favor of newer biologic entrants with alternate mechanisms of action (MOA).

June 12, 2018|

RealTime Dynamix™: Hyperkalemia US Q2 2018 Spotlight

Last week the FDA approved two products, Pfizer’s Retacrit and AstraZeneca’s Lokelma, both of which encountered lengthy regulatory delays. Retacrit is the first biosimilar ESA to enter the US market and will compete with Amgen’s Epogen and Aranesp and Roche’s Mircera. Lokelma (sodium zirconium cyclosilicate) is an oral potassium binder that will compete with Relypsa’s Veltassa which has been unchallenged in the market since its US approval in October 2015.

May 24, 2018|

RealTime Dynamix™: Renal Anemia US Q1 2018 Spotlight II

Last week the FDA approved two products, Pfizer’s Retacrit and AstraZeneca’s Lokelma, both of which encountered lengthy regulatory delays. Retacrit is the first biosimilar ESA to enter the US market and will compete with Amgen’s Epogen and Aranesp and Roche’s Mircera. Lokelma (sodium zirconium cyclosilicate) is an oral potassium binder that will compete with Relypsa’s Veltassa which has been unchallenged in the market since its US approval in October 2015.

May 22, 2018|

RealWorld Dynamix™: DMT New Starts in MS US 2018 Spotlight

Using Biogen’s Tecfidera as an example, we delved into our recent RealWorld Dynamix: DMT New Starts in Multiple Sclerosis audit (n=274 neurologists, n=1,033 patients) to not only understand what drives Tecfidera’s selection as a popular first-line choice but to go deeper and reveal where and why Tecfidera is losing new start multiple sclerosis patients to the competition. 

May 17, 2018|